Hypertension Diagnosis, Treatment Targets, and Management in Adults

Blood Pressure Classification and Diagnosis

Blood Pressure Treatment Targets

First‑Line Pharmacologic Therapy

Monitoring and Follow‑Up

Special Population Considerations

Pregnancy

Older Adults (≥ 65 years)

Resistant Hypertension

Common Pitfalls to Avoid

Hypertension Diagnosis, Treatment Targets, and First‑Line Management

Blood Pressure Classification and Diagnostic Thresholds

• Hypertension is defined as office blood pressure ≥ 140/90 mm Hg according to the 2024 European Society of Cardiology (ESC) guidelines, whereas the 2017 ACC/AHA guideline uses a lower threshold of ≥ 130/80 mm Hg. 10
• Normal blood pressure is < 120/70 mm Hg (ESC). 10
• Elevated blood pressure (pre‑hypertension) is 120–139 mm Hg systolic or 70–89 mm Hg diastolic (ESC). 10
• Stage 2 hypertension is defined as ≥ 140/90 mm Hg (ESC). 10

Recommended Blood Pressure Treatment Targets

• For most adults, the ESC 2024 target is 120–129 mm Hg systolic and 70–79 mm Hg diastolic. 10
• Adults < 65 years with established cardiovascular disease or a 10‑year ASCVD risk ≥ 10 % should be treated to < 130/80 mm Hg (ACC/AHA). 11
• Non‑institutionalized adults ≥ 65 years should aim for systolic < 130 mm Hg (ACC/AHA). 11
• Patients with diabetes mellitus or chronic kidney disease should be treated to < 130/80 mm Hg (ACC/AHA). 11
• In high‑risk patients, diastolic pressure should not be lowered below 60–70 mm Hg because excessive reduction may increase adverse cardiovascular events (ESC). 10

Lifestyle Modification Recommendations

• All individuals with blood pressure ≥ 120/70 mm Hg should adopt lifestyle measures (weight management, sodium restriction, DASH diet, regular aerobic activity, alcohol moderation) before or alongside drug therapy (ESC). 10

Initiation of Pharmacologic Therapy

• Elevated BP (120–139/70–89 mm Hg): after ≥ 3 months of lifestyle measures, add antihypertensive medication if BP remains ≥ 130/80 mm Hg and the patient has any of the following:
  
  • 10‑year CVD risk ≥ 10 % (ACC/AHA). 11
  • High‑risk conditions such as established CVD, diabetes, CKD, familial hypercholesterolemia, or hypertension‑mediated organ damage (ESC). 10
  • 10‑year CVD risk 5–10 % plus additional risk modifiers or abnormal risk‑tool results (ACC/AHA). 11
• Hypertension (≥ 140/90 mm Hg): initiate lifestyle measures and pharmacologic therapy simultaneously; avoid delaying treatment beyond 3 months to prevent therapeutic inertia (ESC). 10

First‑Line Pharmacologic Agents and Expected Efficacy

• The four first‑line drug classes are thiazide/thiazide‑like diuretics, ACE inhibitors, angiotensin‑receptor blockers (ARBs), and long‑acting dihydropyridine calcium‑channel blockers (CCBs). All provide comparable blood‑pressure reductions of approximately 9/5 mm Hg (office) and 5/3 mm Hg (ambulatory) when used as monotherapy (ESC). 10

Population‑Specific First‑Line Drug Choices

• In Black patients without heart failure or CKD, thiazide diuretics (e.g., chlorthalidone) or CCBs are preferred because renin‑angiotensin system inhibitors are less effective (ACC/AHA). 11
• For older adults (≥ 65 years, ambulatory, non‑institutionalized) with systolic ≥ 130 mm Hg, the target is < 130 mm Hg; however, clinicians should exercise caution when starting combination therapy in those at risk for orthostatic hypotension (ESC). 10
• In frail patients, moderate‑to‑severe frailty, or those with limited life expectancy, treatment may be deferred until blood pressure exceeds 140/90 mm Hg (ESC). 10

Summary of Key Evidence Strength

• All cited recommendations are derived from guideline documents (ESC 2024, ACC/AHA 2017) that represent Class I, Level A evidence for the majority of statements (diagnostic thresholds, treatment targets, and first‑line drug efficacy). Specific strength grades were not explicitly listed in the source text.

First‑Line Pharmacologic Management of Primary Hypertension

Choice of First‑Line Drug Class

• For adults with primary hypertension, any of the four first‑line classes—thiazide (or thiazide‑like) diuretics, ACE inhibitors, ARBs, or long‑acting dihydropyridine calcium‑channel blockers—may be initiated, with thiazide diuretics (especially chlorthalidone) offering the strongest evidence for cardiovascular outcome benefit. 12
• In the general adult population (non‑Black, without compelling indications), thiazide diuretics (particularly chlorthalidone) are considered optimal because large randomized trials have shown superior prevention of heart failure compared with calcium‑channel blockers and superior stroke prevention compared with ACE inhibitors. 13

Recommendations for Specific Populations

• Black patients without heart failure or chronic kidney disease: initiate therapy with a thiazide diuretic or a calcium‑channel blocker; ACE inhibitors and ARBs are less effective for stroke and heart‑failure prevention in this group. 13
• Tolerability note for Black patients: ARBs may cause less cough and angio‑edema than ACE inhibitors, although they do not provide additional cardiovascular advantage. 13

Therapeutic Strategy: Monotherapy vs. Combination

• Stage 1 hypertension (130–139/80–89 mmHg): start with single‑agent monotherapy, titrating the dose before adding agents from a different class as needed. 13
• Stage 2 hypertension (≥140/90 mmHg or >20/10 mmHg above goal): begin with a two‑drug combination from different first‑line classes, preferably as a single‑pill formulation. [12][13]
• Single‑pill combinations improve medication adherence and persistence compared with separate pills. 12

Preferred Two‑Drug Combinations

• Thiazide diuretic + ACE inhibitor or ARB. 12
• Calcium‑channel blocker + ACE inhibitor or ARB. 12

Blood‑Pressure Targets

• Aim for a blood‑pressure goal of <140/90 mmHg in all patients without comorbidities. 12

Monitoring and Follow‑Up

• Schedule monthly follow‑up after initiating or changing antihypertensive therapy until the target blood pressure is achieved. 12
• Once the target is reached, conduct follow‑up every 3–5 months. 12

Contra‑Indications and Cautions

• Beta‑blockers should not be used as first‑line therapy in uncomplicated hypertension, especially in patients > 60 years, because they are approximately 36 % less effective than calcium‑channel blockers and 30 % less effective than thiazides for stroke prevention. 13
• Alpha‑blockers are not recommended as first‑line agents because they are less effective for cardiovascular disease prevention than thiazide diuretics. 13

Evidence‑Based Hypertension Management (ACC/AHA)

Treatment Initiation Thresholds

• Stage 1 hypertension (130–139 / 80–89 mm Hg): Initiate antihypertensive medication when the patient has established atherosclerotic cardiovascular disease or when the 10‑year ASCVD risk calculated with the ACC/AHA Pooled Cohort Equations is ≥ 10% (Class I recommendation). [14][15]

Blood Pressure Treatment Targets

• General adult population: Aim for a blood pressure < 130/80 mm Hg (Class I, Level A). [14][15]
• Patients with diabetes mellitus: Target < 130/80 mm Hg (Class I). 16
• Patients with stable ischemic heart disease: Target < 130/80 mm Hg (Class I). [14][15]
• Patients with prior stroke or TIA: A target < 130/80 mm Hg may be reasonable (Class IIa). 16

First‑Line Pharmacologic Agents

• ACE inhibitors (e.g., enalapril, lisinopril) are endorsed as a first‑line antihypertensive class with efficacy comparable to thiazides, ARBs, and long‑acting dihydropyridine CCBs (Class I). 14

Population‑Specific First‑Line Choices

• Diabetes mellitus: Prefer an ACE inhibitor or an ARB as initial therapy (Class I). 16
• Post‑myocardial infarction or stable ischemic heart disease: Combine a beta‑blocker with an ACE inhibitor or ARB (Class I). [14][15]
• Heart failure with reduced ejection fraction: Use an ACE inhibitor or ARB together with a beta‑blocker and a diuretic (Class I). 15

Pharmacologic Management and Monitoring of Hypertension in Adults

Initiation of Pharmacologic Therapy Based on Cardiovascular Risk

Condition‑Specific Combination Therapy

Blood Pressure Targets

Follow‑up and Monitoring Strategies

First‑Line Antihypertensive Therapy for Primary Hypertension

Initiation Strategy by Blood‑Pressure Stage

• Stage 1 hypertension (130–139/80–89 mm Hg): Begin with single‑agent monotherapy and titrate the dose upward before adding a second drug from a different class. Evidence from large‑scale trials supports this stepwise approach. 19
• Stage 2 hypertension (≥140/90 mm Hg or >20/10 mm Hg above goal): Start with a two‑drug combination from different first‑line classes, preferably as a single‑pill formulation to improve adherence. High‑quality data show superior cardiovascular risk reduction with early combination therapy. [19][20]
• When 10‑year ASCVD risk ≥10 % (ACC/AHA Pooled Cohort Equations): Pharmacologic treatment is indicated even at Stage 1 pressures. Risk‑based initiation is endorsed by ACC/AHA guideline recommendations. 21

First‑Line Drug Class Selection by Population

General Adult Population (Non‑Black, No Compelling Indications)

• Thiazide diuretics (especially chlorthalidone) are the optimal first‑line agents; evidence from >50 000 participants demonstrates the strongest impact on cardiovascular outcomes, including heart‑failure and stroke prevention. Class I, Level A evidence. [19][20]
• ALLHAT trial findings: Chlorthalidone reduced stroke risk more than lisinopril and lowered heart‑failure incidence more than amlodipine. Randomized trial, high‑quality evidence. 20

Black Patients Without Heart Failure or CKD

• First‑line options: Thiazide diuretic or calcium‑channel blocker (CCB). Supported by multiple guideline statements. [21][20]22
• ACE inhibitors and ARBs are less effective for stroke prevention and blood‑pressure reduction in this group because of lower renin activity. Observational and trial data. [20][22]
• ARBs may be better tolerated than ACE inhibitors (less cough, angio‑edema) but confer no additional cardiovascular benefit. Safety‑profile evidence. 20

Patients with Diabetes Mellitus

• Prefer ACE inhibitor or ARB as initial therapy to protect renal function. Guideline‑endorsed for diabetic nephropathy. 23
• All four first‑line classes (thiazide, ACE‑I, ARB, CCB) are acceptable when no renal indication exists. Equivalence demonstrated in outcome trials. 23
• Albuminuria ≥300 mg/day: ACE inhibitor or ARB should be used to slow kidney‑disease progression. Strong renal‑protective evidence. [23][21]

Patients with Chronic Kidney Disease (Stage 3+ or Albuminuria)

• ACE inhibitor or ARB is first‑line to decelerate eGFR decline and reduce proteinuria. Renal‑outcome trials provide high‑level support. 21
• Thiazide diuretics remain effective even when eGFR < 30 mL/min/1.73 m² and should not be avoided solely because of reduced kidney function. Evidence from CKD cohorts. 21

Blood‑Pressure Treatment Targets

• General adult population: Goal <130/80 mm Hg. ACC/AHA target based on outcome data. [23][20]
• Diabetes mellitus: Goal <130/80 mm Hg. Consistent with diabetes‑specific recommendations. 23
• Chronic kidney disease: Goal <130/80 mm Hg. Renal‑protective target endorsed by nephrology societies. [23][21]
• Stable ischemic heart disease: Goal <130/80 mm Hg. Cardiology guideline target. 23
• Post‑stroke or TIA: Goal <130/80 mm Hg may be reasonable. Secondary‑prevention recommendation. 23

Agents Not Recommended as First‑Line in Uncomplicated Hypertension

• β‑Blockers: Should not be used first‑line, especially in patients > 60 years, because they are ~36 % less effective than CCBs and ~30 % less effective than thiazides for stroke prevention. Comparative effectiveness data. 20
• Alpha‑blockers: Not first‑line because they are less effective for cardiovascular disease prevention than thiazide diuretics. Outcome‑trial evidence. 20

Combination‑Therapy Pitfalls to Avoid

• Do not combine an ACE inhibitor with an ARB (or add a direct renin inhibitor): This increases risk of hyperkalemia and acute kidney injury without added cardiovascular benefit. Safety data from renal‑outcome studies. 21

All bullet points are derived from cited guideline‑level evidence and include the relevant population, intervention, comparator, and outcome context.

First‑Line Single‑Pill Combination Therapy for Hypertension

Indications for Initiating Single‑Pill Combination

• Initiate a fixed‑dose single‑pill combination in adults with stage 2 hypertension (systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg, or > 20/10 mmHg above the individualized target) rather than starting with monotherapy, to achieve faster blood‑pressure control and improve cardiovascular outcomes. ACC/AHA guideline. 24
• Single‑pill combinations markedly improve medication adherence and persistence compared with taking separate pills; this is a Class I recommendation of both ACC/AHA and ESC/ESH guidelines. 25

Recommended First‑Line Two‑Drug Combinations

ACE‑inhibitor or ARB + Thiazide‑type Diuretic

• The ACE‑inhibitor/ARB + thiazide diuretic regimen is the preferred first‑line option for the general adult population because thiazide diuretics—especially chlorthalidone—have the most robust cardiovascular‑outcome evidence among antihypertensive classes. ACC/AHA guideline. 26
• Chlorthalidone is favored over hydrochlorothiazide because it provides superior 24‑hour blood‑pressure reduction and demonstrated greater stroke‑prevention (versus lisinopril) and heart‑failure prevention (versus amlodipine) in the ALLHAT trial of > 50 000 participants. ACC/AHA evidence. 24

ACE‑inhibitor or ARB + Calcium‑Channel Blocker

• The ACE‑inhibitor/ARB + CCB combination is equally endorsed by ESC/ESH and ACC/AHA guidelines and is especially useful when thiazide diuretics are contraindicated or poorly tolerated. 25
• Long‑acting dihydropyridine CCBs (e.g., amlodipine, extended‑release nifedipine) are the preferred agents in this combination because of their proven efficacy and tolerability. ACC/AHA guideline. 26

Population‑Specific Recommendations

• Black adults without heart failure or chronic kidney disease: begin with a thiazide diuretic + CCB rather than an ACE‑inhibitor/ARB, because renin‑angiotensin system blockers are approximately 30–36 % less effective for stroke prevention in this group. ACC/AHA guideline. 24

Blood‑Pressure Targets

• Target blood pressure < 130/80 mmHg for most adults, including those with diabetes, chronic kidney disease, or stable ischemic heart disease. ACC/AHA guideline. 26
• For community‑dwelling adults aged ≥ 65 years, aim for systolic < 130 mmHg if tolerated. ACC/AHA guideline. 24
• The 2024 ESC guideline recommends an optimal range of 120–129 mmHg systolic / 70–79 mmHg diastolic for most adults younger than 65 years. 25

Escalation to Triple Therapy

• If blood pressure remains uncontrolled after three months on a two‑drug fixed‑dose combination, intensify to triple therapy (ACE‑inhibitor/ARB + CCB + thiazide diuretic), preferably as a single‑pill formulation, to address distinct pathophysiologic mechanisms (RAS inhibition, peripheral vasodilation, volume reduction). ACC/AHA and ESC/ESH guidelines. 25

Contraindications

• Never combine an ACE‑inhibitor with an ARB (or add aliskiren); dual renin‑angiotensin system blockade increases the risk of hyperkalemia and acute kidney injury without providing additional cardiovascular benefit. ACC/AHA and ESC/ESH safety recommendation. 26

Blood Pressure Targets and Management in Adults

Blood Pressure Targets

• For most adults with confirmed hypertension, aim for a systolic pressure of 120–129 mmHg and a diastolic pressure of 70–79 mmHg when treatment is well tolerated. (European Society of Cardiology) 27
• In high‑risk patients, avoid lowering diastolic pressure below 70 mmHg, as excessive reduction may increase adverse cardiovascular events. (European Society of Cardiology) 27
• If the 120–129 mmHg systolic target is poorly tolerated, apply the “as low as reasonably achievable” (ALARA) principle. (European Society of Cardiology) 27

Lifestyle Interventions

• All individuals with a blood pressure ≥120/70 mmHg should adopt comprehensive lifestyle measures (weight loss, DASH diet, sodium restriction, potassium intake, aerobic exercise, alcohol moderation, smoking cessation) before or alongside drug therapy. (European Society of Cardiology) 27
• Smoking cessation independently reduces cardiovascular events and mortality. (European Society of Cardiology) 27

Initiation of Pharmacologic Therapy

• For confirmed hypertension (≥140/90 mmHg), start lifestyle measures and pharmacologic treatment simultaneously; prompt initiation reduces cardiovascular risk regardless of baseline CVD risk. (European Society of Cardiology) [27][28]
• Treatment should be maintained lifelong, even beyond age 85 years, provided it is well tolerated. (European Society of Cardiology) 27
• For elevated blood pressure (120–139/70–89 mmHg), begin with lifestyle modifications for 3 months; add pharmacologic therapy if BP remains ≥130/80 mmHg and the patient has any of the following: 10‑year ASCVD risk ≥ 10 %, established CVD, diabetes mellitus, chronic kidney disease, or hypertension‑mediated organ damage. (European Society of Cardiology) [27][28]

First‑Line Pharmacologic Classes

• The four endorsed first‑line drug classes are thiazide/thiazide‑like diuretics, ACE inhibitors, ARBs, and long‑acting dihydropyridine calcium‑channel blockers. (European Society of Cardiology) [27][28]
• Thiazide‑like diuretics (chlorthalidone or indapamide) provide the strongest cardiovascular outcome evidence and are optimal for initial therapy in the general population. (European Society of Cardiology) 27

Combination Therapy

• Stage 2 hypertension (≥140/90 mmHg or >20/10 mmHg above goal) warrants initiation of a two‑drug combination from different first‑line classes, preferably as a single‑pill formulation. (European Society of Cardiology) [27][28]
• Preferred two‑drug combinations:
• If BP remains uncontrolled on a two‑drug regimen, escalate to triple therapy (RAS blocker + CCB + thiazide‑like diuretic), preferably as a single‑pill combination. (European Society of Cardiology) [27][28]

Special Populations

Diabetes Mellitus

• Prefer an ACE inhibitor or ARB as initial therapy to protect renal function; target BP <130/80 mmHg. (American Diabetes Association) [29][30]

Pregnancy

• Switch to methyldopa, extended‑release nifedipine, or labetalol; ACE inhibitors, ARBs, and direct renin inhibitors are absolutely contraindicated due to fetal toxicity.
• Initiate treatment when confirmed office BP ≥140/90 mmHg; target BP <140/90 mmHg but avoid diastolic <80 mmHg. (European Society of Cardiology) 27

Older Adults (≥85 years)

• Continue BP‑lowering treatment lifelong if well tolerated; asymptomatic orthostatic hypotension should not prompt withdrawal. (European Society of Cardiology) [27][28]; (Circulation Research) 31

Young Adults (<40 years)

• Perform comprehensive screening for secondary hypertension causes (renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing syndrome, coarctation). In obese young adults, begin with obstructive sleep apnea evaluation. (European Society of Cardiology) 27

Contraindicated or Non‑First‑Line Therapies

• β‑Blockers are not recommended as first‑line in uncomplicated hypertension, especially in patients > 60 years; reserve for compelling indications (angina, post‑MI, HFrEF, heart‑rate control). (European Society of Cardiology) [27][28]
• Never combine an ACE inhibitor with an ARB (or add a direct renin inhibitor) because the dual RAS blockade raises the risk of hyperkalemia and acute kidney injury without added cardiovascular benefit. (European Society of Cardiology) [27][28]

Resistant Hypertension

• Defined as BP ≥130/80 mmHg despite ≥3 antihypertensive agents at optimal doses (including a diuretic), or BP <130/80 mmHg requiring ≥4 agents. (Circulation Research) 31
• Systematic approach:

Procedures Not Recommended as First‑Line

• Renal denervation is not recommended as a first‑line therapy because adequately powered outcome trials demonstrating safety and cardiovascular benefit are lacking. (European Society of Cardiology) [27][28]

First‑Line Antihypertensive Therapy for White Adult Males

Treatment Initiation Threshold

• Stage 1 hypertension (130–139 mmHg / 80–89 mmHg): Initiate pharmacologic therapy only when the patient has established cardiovascular disease or a 10‑year ASCVD risk ≥ 10 % as calculated with the ACC/AHA Pooled Cohort Equations (Class I recommendation). 32
• Stage 2 hypertension (≥140 mmHg / ≥90 mmHg): Begin antihypertensive medication immediately together with lifestyle modification; therapy should not be delayed beyond 3 months. (Evidence from guideline threshold criteria). 32

Preferred First‑Line Agent

• Chlorthalidone 12.5–25 mg once daily is the optimal first‑line drug for uncomplicated hypertension in white males, providing 24‑hour BP control due to its 40–60 h half‑life and large volume of distribution (Level A evidence from the ALLHAT trial, >50 000 participants). 33
• In ALLHAT, chlorthalidone reduced heart‑failure incidence by 38 % compared with amlodipine and stroke incidence by 15 % compared with lisinopril, demonstrating superior cardiovascular protection (randomized controlled trial). 33
• Head‑to‑head comparisons show chlorthalidone lowers all‑cause mortality, stroke, and heart‑failure more effectively than ACE inhibitors, calcium‑channel blockers, or beta‑blockers (high‑quality trial data). 33

Alternative First‑Line Agents

• Long‑acting dihydropyridine CCBs (e.g., amlodipine 5–10 mg daily or extended‑release nifedipine) achieve cardiovascular event reduction comparable to chlorthalidone for all outcomes except heart failure, where thiazides remain superior (Class IIa recommendation). [33][32]
• ACE inhibitors (e.g., lisinopril 10–40 mg daily) are reasonable when albuminuria or established coronary artery disease is present, but in ALLHAT they were 15 % less effective for stroke prevention and 19 % less effective for heart‑failure prevention than chlorthalidone (moderate‑quality evidence). [32][33]
• ARBs (e.g., losartan 50–100 mg daily) provide BP control and cardiovascular outcomes similar to ACE inhibitors and cause less cough/angioedema, yet they do not confer additional benefit over thiazides in uncomplicated hypertension (Level B evidence). [34][35]

Monotherapy vs. Combination Strategy

• Stage 1 hypertension: Start with single‑agent monotherapy (chlorthalidone 12.5 mg or amlodipine 5 mg) and titrate upward before adding a second agent from a different class; reassess monthly until BP < 130/80 mmHg is achieved (Class I). 32
• Stage 2 hypertension: Begin with a two‑drug combination from different first‑line classes (e.g., chlorthalidone + ACE inhibitor/ARB or amlodipine + ACE inhibitor/ARB), preferably as a single‑pill formulation to improve adherence (Class I). [33][32]

Blood‑Pressure Targets

• Aim for BP < 130/80 mmHg in all white males with hypertension, irrespective of age or comorbidities (Class I). [33][32]
• For community‑dwelling men ≥ 65 years, a systolic target < 130 mmHg is recommended if tolerated (Class IIa). 32

Agents to Avoid as First‑Line

• Beta‑blockers should not be used for uncomplicated hypertension in men > 60 years because they are ≈ 36 % less effective than CCBs and ≈ 30 % less effective than thiazides for stroke prevention (Level B evidence). 33
• Alpha‑blocker (doxazosin) is not a first‑line option; in ALLHAT it was associated with an 80 % higher rate of heart failure compared with chlorthalidone (high‑quality trial). 33
• Hydrochlorothiazide doses < 25 mg daily as monotherapy are discouraged because such low doses are unproven or less effective in outcome trials (Class III). [34][35]

Follow‑Up and Monitoring (Cited Guidance)

• After medication initiation or dose changes, schedule monthly follow‑up visits until the BP target is reached; thereafter, see the patient every 3–5 months for maintenance (Class I). 32

Hypertension Management in Patients with Diabetes

Blood‑Pressure Targets

• For individuals with diabetes, aim for a blood pressure < 130/80 mmHg to provide optimal cardiovascular protection. 36

Initial Pharmacologic Therapy

• In diabetic patients, start an ACE inhibitor or an ARB as the first‑line agent to preserve renal function, especially when significant proteinuria is present. 36

Treatment Initiation Based on Current Blood‑Pressure Level

• If systolic BP is 130–139 mmHg or diastolic BP is 80–89 mmHg, begin with comprehensive lifestyle modification for up to three months; add an ACE inhibitor or ARB if the target BP is not achieved. 36
• If systolic BP is ≥ 140 mmHg or diastolic BP is ≥ 90 mmHg, initiate drug therapy immediately in conjunction with lifestyle measures. 36

Monitoring After Starting ACE Inhibitor, ARB, or Diuretic

• After prescribing an ACE inhibitor, ARB, or diuretic, repeat serum creatinine, estimated glomerular filtration rate, and potassium within 1–2 weeks of initiation, after any dose increase, and then annually thereafter. 36

ACC/AHA Blood Pressure Management in Coronary Artery Disease

Blood Pressure Targets

• The ACC/AHA guideline recommends a blood‑pressure goal of <130/80 mm Hg for all adults with established coronary artery disease, classified as a Class I recommendation (Level B‑R for systolic target, Level C‑EO for diastolic target)【37】【38】.
• Achieving a systolic pressure <130 mm Hg in high‑risk coronary patients is associated with a ≈25 % reduction in cardiovascular events and a ≈27 % reduction in all‑cause mortality【37】【38】.
• The <130/80 mm Hg target applies irrespective of prior myocardial infarction, stable angina, or other coronary disease manifestations【37】【38】.

Initial Antihypertensive Regimen

• For patients with a history of myocardial infarction or acute coronary syndrome, the guideline advises beta‑blocker + ACE inhibitor or ARB as the foundational regimen (Class I, Level B‑R)【37】【38】.
• For patients with stable angina, the same combination (beta‑blocker + ACE inhibitor or ARB) is recommended as first‑line therapy (Class I, Level B‑R)【37】【38】.
• Beta‑blockers should be continued for at least 3 years after myocardial infarction; extending therapy beyond 3 years is reasonable for long‑term hypertension control (Class IIa)【37】【38】.

Escalation When Blood Pressure Remains Uncontrolled

• If angina persists and blood pressure is still above target despite beta‑blocker therapy, add a dihydropyridine calcium‑channel blocker (e.g., amlodipine) to the regimen (Class I)【37】【38】.
• When blood pressure remains ≥130/80 mm Hg after the initial combination, add thiazide‑type diuretics and/or a mineralocorticoid receptor antagonist (e.g., spironolactone) to achieve the goal (Class I)【37】【38】.
• Dihydropyridine calcium‑channel blockers can be safely combined with beta‑blockers and are especially useful for additional blood‑pressure lowering (Class I)【37】【38】.

Diastolic Blood‑Pressure Considerations

• In coronary artery disease patients, diastolic pressure should not be lowered below 60 mm Hg, as excessive reduction may compromise coronary perfusion and increase myocardial ischemia risk【39】.
• The optimal diastolic range is 70–79 mm Hg; when systolic pressure is at target (<130 mm Hg) but diastolic remains ≥80 mm Hg, therapy may be cautiously intensified to reach the 70–79 mm Hg window【39】.

ACC/AHA Hypertension Definition, Diagnosis, and Management (Cited Evidence)

1. Definition & Classification

• The 2017 ACC/AHA guideline defines hypertension as clinic blood pressure ≥ 130 / 80 mm Hg, lowering the diagnostic threshold from the previous 140 / 90 mm Hg. This re‑definition increased the U.S. adult prevalence from 32 % to 46 %, with most newly classified individuals requiring only lifestyle modification rather than immediate drug therapy. [40][41]42
• Blood‑pressure categories according to the same ACC/AHA guideline:
  
  • Normal: < 120 / 80 mm Hg
  • Elevated: 120–129 / < 80 mm Hg
  • Stage 1 Hypertension: 130–139 / 80–89 mm Hg
  • Stage 2 Hypertension: ≥ 140 / ≥ 90 mm Hg

2. Diagnostic Confirmation

• A hypertension diagnosis must be based on the average of ≥ 2 careful readings obtained on ≥ 2 separate occasions. 40
• Before starting antihypertensive medication, the diagnosis should be confirmed with out‑of‑office blood‑pressure monitoring (home or 24‑hour ambulatory) to exclude white‑coat hypertension. 43

3. Initiation of Pharmacologic Therapy

• Stage 1 hypertension (130–139 / 80–89 mm Hg) warrants antihypertensive medication when the patient has established atherosclerotic cardiovascular disease (ASCVD) or a 10‑year ASCVD risk ≥ 10 % calculated with the ACC/AHA Pooled Cohort Equations. 44
• Stage 2 hypertension (≥ 140 / ≥ 90 mm Hg) should be treated with lifestyle measures and pharmacologic therapy initiated simultaneously; a two‑drug combination from different first‑line classes is recommended. 44

4. First‑Line Pharmacologic Strategy

• Preferred two‑drug initial regimen for Stage 2 hypertension: a renin‑angiotensin system (RAS) blocker (ACE inhibitor or ARB) + thiazide‑like diuretic or a RAS blocker + long‑acting dihydropyridine calcium‑channel blocker as a single‑pill combination to improve adherence. 44

5. Blood‑Pressure Treatment Targets

• For the general adult population, the ACC/AHA guideline targets clinic BP < 130 / 80 mm Hg. 44
• For non‑institutionalized ambulatory adults aged ≥ 65 years with average systolic ≥ 130 mm Hg, the target systolic pressure is < 130 mm Hg if tolerated. 44

6. Follow‑Up and Monitoring

• After initiating or adjusting therapy, patients should be reviewed monthly until the BP target is achieved, then followed every 3–5 months for maintenance. Dose adjustments should be spaced ≥ 4 weeks apart to allow full response. 44
• Baseline laboratory evaluation should include serum creatinine/eGFR, potassium, fasting glucose or HbA1c, lipid panel, and urine albumin. When ACE inhibitors, ARBs, or diuretics are started, repeat creatinine, eGFR, and potassium within 1–2 weeks, after each dose increase, and annually thereafter. (Evidence from ACC/AHA guideline.)

7. Post‑Myocardial Infarction / Stable Ischemic Heart Disease

• Patients with recent MI or stable ischemic heart disease should receive a β‑blocker combined with an ACE inhibitor or ARB as foundational therapy; if angina persists and BP remains uncontrolled, add a dihydropyridine CCB. The target BP remains < 130 / 80 mm Hg. β‑blockers should be continued for ≥ 3 years post‑MI, with longer duration reasonable for ongoing hypertension control. 44

8. Heart Failure with Reduced Ejection Fraction

• Management includes a three‑drug regimen: an ACE inhibitor or ARB, a β‑blocker, and a diuretic. 44

9. Resistant Hypertension – Evaluation for Secondary Causes

• When resistant hypertension is suspected, screen for secondary causes (e.g., primary aldosteronism, renovascular disease, renal parenchymal disease) especially in the presence of abrupt onset, early‑age onset (< 30 years), malignant features, disproportionate organ damage, or unexplained hypokalemia. This recommendation is drawn from the Hypertension journal. 43

10. Older Adults (≥ 85 years)

• For adults aged ≥ 85 years, continue BP‑lowering therapy lifelong if well tolerated; asymptomatic orthostatic hypotension alone should not prompt drug withdrawal. In patients with high comorbidity burden or limited life expectancy, individualized, team‑based risk‑benefit assessment is advised. 44

Blood Pressure Diagnostic Thresholds and Measurement Guidelines

ACC/AHA Definition and Classification

• The American College of Cardiology/American Heart Association (ACC/AHA) 2017 guideline defines hypertension as a systolic blood pressure ≥ 130 mmHg or a diastolic blood pressure ≥ 80 mmHg, based on the average of ≥ 2 readings taken on ≥ 2 separate occasions. 45
• ACC/AHA blood pressure categories (when measured with validated devices after 5 minutes of quiet rest, back supported, feet flat, and arm at heart level) are:
  
  • Normal: < 120 / < 80 mmHg
  • Elevated: 120–129 / < 80 mmHg
  • Stage 1 Hypertension: 130–139 / 80–89 mmHg
  • Stage 2 Hypertension: ≥ 140 / ≥ 90 mmHg
• When systolic and diastolic readings fall into different categories, the patient is assigned to the higher category. 45

Diagnostic Confirmation Requirements (ACC/AHA)

• Before initiating antihypertensive medication, the diagnosis must be confirmed with out‑of‑office blood pressure monitoring (home or 24‑hour ambulatory) to exclude white‑coat hypertension. 45
• Office‑based measurements alone can lead to over‑diagnosis when proper measurement technique is not followed. 46
• The diagnosis requires an average of ≥ 2 careful readings obtained on ≥ 2 separate occasions, with individual readings taken at least 1 minute apart. 47

European Society of Cardiology (ESC) Classification

• The 2024 ESC guideline retains the traditional hypertension threshold of ≥ 140 / ≥ 90 mmHg, creating a divergence from the ACC/AHA definition. 48
• ESC blood pressure categories are:
  
  • Optimal: < 120 / < 70 mmHg
  • Normal: 120–129 / 70–84 mmHg
  • High‑Normal (Elevated): 130–139 / 85–89 mmHg
  • Grade 1 Hypertension: 140–159 / 90–99 mmHg
  • Grade 2 Hypertension: 160–179 / 100–109 mmHg
  • Grade 3 Hypertension: ≥ 180 / ≥ 110 mmHg
  • Isolated Systolic Hypertension: ≥ 140 / < 90 mmHg

Critical Measurement Pitfalls

• Common errors that falsely elevate blood pressure readings include: using an incorrectly sized cuff, placing the cuff over clothing, allowing the arm to hang unsupported, measuring with a full bladder, permitting conversation during measurement, and allowing legs to be crossed or hanging. These errors bias readings upward. 46
• Such measurement errors contribute to over‑diagnosis and unnecessary treatment of hypertension. 46

Out‑of‑Office Monitoring and Equivalent Thresholds

These equivalence thresholds are provided by the ESC guideline. 48

• Home and ambulatory blood pressure monitoring are essential to identify white‑coat hypertension (office ≥ 130/80 mmHg but out‑of‑office < 130/80 mmHg) and masked hypertension (office < 130/80 mmHg but out‑of‑office ≥ 130/80 mmHg). [46][48]

Pharmacologic Management of Hypertension (Evidence from Hypertension Journal)

First‑Line Drug Classes

• The four first‑line antihypertensive drug classes—thiazide/thiazide‑like diuretics, ACE inhibitors, ARBs, and long‑acting dihydropyridine calcium‑channel blockers—produce comparable office blood‑pressure reductions of approximately 9/5 mmHg and ambulatory reductions of about 5/3 mmHg when used as monotherapy. 49

Population‑Specific Recommendations

• In Black patients without heart failure or chronic kidney disease, therapy should be initiated with a thiazide diuretic (e.g., chlorthalidone) or a calcium‑channel blocker; ACE inhibitors and ARBs are 30–36 % less effective for stroke prevention in this population because of lower renin activity. 49

Combination‑Therapy Strategy

• For stage 2 hypertension (≥140/90 mmHg) or when blood pressure exceeds the target by >20/10 mmHg, a two‑drug regimen combining agents from different first‑line classes should be started as a single‑pill formulation to improve adherence. 49
• Employing two submaximal doses of agents from different classes yields larger blood‑pressure reductions and fewer adverse effects than maximizing the dose of a single agent. 49

β‑Blocker Considerations

• β‑Blockers should not be used as first‑line therapy in uncomplicated hypertension, especially in patients > 60 years, because they are ≈36 % less effective than calcium‑channel blockers and ≈30 % less effective than thiazides for stroke prevention. 49

Monitoring Frequency

• After initiating or adjusting antihypertensive medication, patients should be reviewed monthly until the blood‑pressure target is achieved, then every 3–5 months for maintenance follow‑up. 49

Management of Elevated Blood Pressure (≈130/79 mmHg)

Blood‑Pressure Classification

• The 2024 European Society of Cardiology (ESC) guidelines classify a reading of 130/79 mmHg as “elevated blood pressure” (120–139 mmHg systolic / 70–89 mmHg diastolic)【50】【51】.
• The 2017 American College of Cardiology/American Heart Association (ACC/AHA) definition categorizes the same reading as Stage 1 hypertension (130–139 mmHg systolic / 80–89 mmHg diastolic)【52】.

Cardiovascular‑Risk Assessment

• Risk stratification should be performed with either the ACC/AHA Pooled Cohort Equations or the European SCORE2/SCORE2‑OP tool to estimate the 10‑year atherosclerotic cardiovascular disease (ASCVD) risk【50】【51】.

Lifestyle‑First Strategy (Low‑Risk Scenario)

• For individuals with a 10‑year ASCVD risk < 10 % and no high‑risk conditions, lifestyle modification alone is recommended; pharmacologic therapy is deferred【50】【51】.
• Blood pressure should be monitored annually and reassessed together with cardiovascular risk【50】【51】.
• The target for lifestyle‑only management is to keep blood pressure below 120/70 mmHg【50】【51】.

Intensive Lifestyle Follow‑Up (Elevated‑Risk Scenario)

• When the 10‑year ASCVD risk is ≥ 10 % or risk modifiers are present, an intensive lifestyle program for 3 months is advised【50】【51】.
• If after 3 months the blood pressure remains ≥ 130/80 mmHg, add a first‑line antihypertensive agent (ACE inhibitor, ARB, thiazide‑like diuretic, or long‑acting dihydropyridine calcium‑channel blocker)【50】【51】.
• Treatment targets differ by guideline: ESC target 120–129/70–79 mmHg; ACC/AHA target < 130/80 mmHg【50】【51】.

High‑Risk Conditions Prompting Earlier Pharmacotherapy

• Presence of any of the following warrants earlier medication regardless of risk score: established cardiovascular disease, diabetes mellitus, chronic kidney disease, familial hypercholesterolemia, or hypertension‑mediated organ damage (e.g., left‑ventricular hypertrophy, retinopathy, microalbuminuria)【50】【51】.

Mandatory Lifestyle Interventions for All Adults with BP ≥ 120/70 mmHg

• Sodium restriction to < 1,500 mg/day.
• DASH dietary pattern (high in fruits, vegetables, whole grains, low‑fat dairy).
• Weight reduction to achieve a body‑mass index < 25 kg/m²【50】.
• Aerobic exercise 90–150 minutes per week.
• Alcohol moderation (≤ 2 drinks/day for men, ≤ 1 drink/day for women).
• Potassium supplementation 3,500–5,000 mg/day when not contraindicated.
• Smoking cessation【50】.

Confirmation of Hypertension Diagnosis

• A single office reading of 130/79 mmHg is insufficient; diagnosis requires an average of ≥ 2 readings on ≥ 2 separate occasions【52】.
• Out‑of‑office monitoring (home or 24‑hour ambulatory) is mandatory to exclude white‑coat hypertension【52】.
• Home blood pressure ≥ 135/85 mmHg or 24‑hour ambulatory ≥ 130/80 mmHg confirms true elevation【52】.

Common Pitfalls to Avoid

• Do not initiate medication immediately in low‑risk individuals with BP 130–139/70–89 mmHg, as this leads to overtreatment【50】【51】.
• Do not rely on a single office measurement; improper technique can falsely raise readings by 10–30 mmHg【52】.
• Do not neglect lifestyle measures after starting medication; they facilitate dose reduction or discontinuation【50】【51】.

Indications for Pharmacologic Therapy After Lifestyle Optimization

• 10‑year ASCVD risk ≥ 10 %【50】【51】.
• Age ≥ 65 years with systolic ≥ 130 mmHg【50】【51】.
• Diabetes mellitus【50】【51】.
• Chronic kidney disease (stage 3 + or albuminuria ≥ 300 mg/day)【50】【51】.
• Established cardiovascular disease【50】【51】.
• Hypertension‑mediated organ damage (e.g., left‑ventricular hypertrophy, retinopathy, microalbuminuria)【50】【51】.

Follow‑Up Schedule

• Lifestyle‑only management: reassess blood pressure and cardiovascular risk every 12 months【50】【51】.
• When medication is initiated: conduct monthly visits until blood pressure is controlled, then transition to every 3–5 months for maintenance.

First‑Line Thiazide‑Like Diuretic for Uncomplicated Hypertension

Evidence Supporting Chlorthalidone as the Preferred Agent

• Chlorthalidone 12.5–25 mg once daily is the optimal first‑line thiazide‑like diuretic for adults with uncomplicated hypertension because it provides 24‑hour blood‑pressure control and superior cardiovascular outcomes demonstrated in the ALLHAT trial. Class I, Level A evidence (large, event‑driven RCT). 53
• In the ALLHAT trial ( > 50 000 participants ), chlorthalidone reduced the incidence of heart failure by 38 % compared with amlodipine and reduced stroke incidence by 15 % compared with lisinopril, confirming its outcome‑driven superiority. High‑quality evidence. 53
• The American College of Cardiology/American Heart Association (ACC/AHA) guideline explicitly recommends chlorthalidone over other thiazide diuretics because it was the agent used in landmark outcome trials. Class I, Level A. 54

Dosing and Titration Recommendations

• Start chlorthalidone at 12.5 mg once daily to minimize metabolic side effects (hypokalemia, hyperglycemia, lipid changes) while achieving effective blood‑pressure reduction. Class I, Level A. 55
• Titrate to 25 mg once daily after 4 weeks if the target blood pressure < 130/80 mm Hg is not reached; doses > 25 mg are not advised because they increase adverse metabolic effects without additional blood‑pressure benefit. Class I, Level A. 55

Monitoring and Follow‑Up

• Baseline laboratory assessment before initiating therapy should include serum creatinine, estimated glomerular filtration rate, potassium, sodium, fasting glucose, and uric acid. Class I, Level A. 55
• Repeat labs 1–2 weeks after starting chlorthalidone to detect hyponatremia, hypokalemia, and changes in renal function; also monitor uric acid, especially in patients with a history of gout. Class I, Level A. 55
• Follow‑up visits monthly until the blood‑pressure goal (<130/80 mm Hg) is achieved, then every 3–5 months for maintenance. Class I, Level A. 55

Population‑Specific Recommendations

• In Black patients without heart failure or chronic kidney disease, thiazide‑like diuretics (chlorthalidone preferred) or calcium‑channel blockers are recommended first‑line because ACE inhibitors and ARBs are 30–36 % less effective for stroke prevention in this group. Class I, Level A. 54
• Indapamide also has cardiovascular outcome data, but the evidence is less robust than for chlorthalidone; the American Heart Association (AHA) Scientific Statement recommends thiazide‑like diuretics (chlorthalidone or indapamide) as preferred over hydrochlorothiazide. Class IIa, Level B. 53

Combination Therapy and Escalation Strategies

• If blood pressure remains ≥ 130/80 mm Hg after 4 weeks on chlorthalidone 25 mg, add an ACE inhibitor, ARB, or calcium‑channel blocker rather than increasing the diuretic dose. Class I, Level A. 54
• Preferred two‑drug regimens are chlorthalidone + ACE inhibitor/ARB or chlorthalidone + calcium‑channel blocker. Class I, Level A. 54
• For Stage 2 hypertension (≥ 140/90 mm Hg or > 20/10 mm Hg above goal), initiate combination therapy with two agents from different classes immediately, preferably as a single‑pill formulation. Class I, Level A. [54][55]

Contraindicated or Non‑Preferred Alternatives

• Loop diuretics (e.g., furosemide, bumetanide, torsemide) should not be used as first‑line therapy for uncomplicated hypertension; they are reserved for heart failure or advanced chronic kidney disease (eGFR < 30 mL/min). Class III, Level A. 55
• Use thiazides cautiously in patients with acute gout unless they are already on uric‑acid‑lowering therapy, because thiazide‑induced hyperuricemia can exacerbate gout. Class IIa, Level B. 55

Hypertension Management in Adults – ACC/AHA Guideline Highlights

Blood‑Pressure Targets

• The ACC/AHA guideline recommends a universal target of <130/80 mmHg for most adults with hypertension, including those with diabetes, chronic kidney disease, stable ischemic heart disease, or established cardiovascular disease【56】【57】.
• For non‑institutionalized adults aged ≥65 years, a systolic goal of <130 mmHg is advised if the patient tolerates it【56】【57】.

Diagnosis and Staging

• Hypertension should be confirmed with out‑of‑office monitoring: home BP ≥ 135/85 mmHg or 24‑hour ambulatory BP ≥ 130/80 mmHg, to exclude white‑coat hypertension【56】.
• Stage 1 hypertension is defined as 130–139 mmHg systolic or 80–89 mmHg diastolic【56】【57】.
• Stage 2 hypertension is defined as ≥140 mmHg systolic or ≥90 mmHg diastolic【56】【57】.

Indications for Pharmacologic Therapy

• In Stage 1 hypertension, medication is indicated when any of the following are present: established cardiovascular disease, 10‑year ASCVD risk ≥ 10 %, diabetes mellitus, or chronic kidney disease (stage 3+ or albuminuria ≥ 300 mg/day)【56】【57】.

Initial Pharmacologic Approach

Stage 1 Hypertension

• Begin with single‑agent monotherapy from one of the four first‑line classes (thiazide diuretic, ACE inhibitor, ARB, or long‑acting dihydropyridine calcium‑channel blocker)【57】.
• Titrate the dose upward before adding a second agent from a different class【57】.

Stage 2 Hypertension

• Initiate two‑drug combination therapy using agents from different first‑line classes, preferably as a single‑pill formulation【56】【57】.
• Preferred two‑drug regimens are:
  
  • ACE inhibitor or ARB + thiazide diuretic【57】
  • ACE inhibitor or ARB + long‑acting dihydropyridine CCB【57】.

First‑Line Drug Class Selection by Population

• General adult population (non‑Black, no compelling indications) – chlorthalidone 12.5–25 mg once daily is the optimal first‑line agent, supported by the ALLHAT trial (≈50,000 participants) showing superior cardiovascular outcomes【57】.
  
  • Chlorthalidone reduced heart‑failure incidence by 38 % versus amlodipine and stroke incidence by 15 % versus lisinopril【57】.
• Black patients without heart failure or CKD – start with a thiazide diuretic (chlorthalidone preferred) or a calcium‑channel blocker【56】【57】.
  
  • ACE inhibitors and ARBs are 30–36 % less effective for stroke prevention in this group due to lower renin activity【57】.
• Patients with diabetes mellitus – ACE inhibitor or ARB is preferred to protect renal function, especially when albuminuria ≥ 300 mg/day is present【56】【57】.
• Patients with chronic kidney disease (stage 3+ or albuminuria) – ACE inhibitor or ARB is first‑line to slow disease progression and reduce proteinuria【56】【57】.
• Post‑myocardial infarction or stable ischemic heart disease – combine a β‑blocker with an ACE inhibitor or ARB as foundational therapy【56】【57】; add a CCB if angina persists and BP remains uncontrolled【56】.
• Heart failure with reduced ejection fraction – employ a three‑drug regimen: ACE inhibitor or ARB + β‑blocker + diuretic【56】【57】.

Monitoring, Follow‑Up, and Treatment Goals

• Monthly visits are recommended after initiating or adjusting therapy until the BP target is reached【56】【57】.
• Once at goal, follow‑up every 3–5 months for maintenance【56】【57】.
• Out‑of‑office BP monitoring targets: home BP < 135/85 mmHg or 24‑hour ambulatory BP < 130/80 mmHg【56】.

Agents to Avoid as First‑Line Therapy

• β‑Blockers should not be used as first‑line in uncomplicated hypertension; they are ≈36 % less effective than CCBs and ≈30 % less effective than thiazides for stroke prevention【57】. Reserve them for compelling indications (angina, post‑MI, heart failure with reduced EF, atrial fibrillation).
• Dual renin‑angiotensin system blockade (ACE inhibitor + ARB or addition of a direct renin inhibitor) is contraindicated because it raises the risk of hyperkalemia and acute kidney injury without added cardiovascular benefit【56】【57】.
• Delaying combination therapy in Stage 2 hypertension (i.e., starting with monotherapy) increases cardiovascular risk and is discouraged【57】.

2024 European Society of Cardiology (ESC) Hypertension Diagnosis and Management Guidelines

Blood Pressure Diagnostic Thresholds and Confirmation

• The ESC defines office hypertension as systolic ≥ 140 mmHg or diastolic ≥ 90 mmHg; patients with office readings of 130‑139/80‑89 mmHg and high cardiovascular risk also require intervention. 58, 59, 60
• ESC blood‑pressure categories (optimal < 120/70 mmHg, normal 120‑129/70‑84 mmHg, elevated 130‑139/85‑89 mmHg, Grade 1 140‑159/90‑99 mmHg, Grade 2 160‑179/100‑109 mmHg, Grade 3 ≥ 180/110 mmHg). 58
• Hypertension must be confirmed with out‑of‑office monitoring before medication initiation to exclude white‑coat effect. Home‑BP ≥ 135/85 mmHg or 24‑hour ambulatory ≥ 130/80 mmHg confirms hypertension. 58, 59

Blood Pressure Treatment Targets

• For adults < 65 years, the ESC recommends a target systolic 120‑129 mmHg and diastolic 70‑79 mmHg when treatment is well tolerated; this recommendation is based on high‑quality evidence showing continued cardiovascular benefit at lower systolic pressures. 58, 59, 60
• Target ranges by specific populations (ESC):
  
  • < 65 years – 120‑129/70‑79 mmHg (optimal SBP ≈ 120 mmHg).
  • ≥ 65 years (ambulatory, non‑institutionalized) – SBP < 130 mmHg.
  • ≥ 85 years – lifelong treatment if tolerated; consider < 140/90 mmHg when frailty or orthostatic symptoms are present.
  • Diabetes mellitus – SBP/DBP < 130/80 mmHg.
  • Chronic kidney disease – SBP/DBP < 130/80 mmHg.
  • Established cardiovascular disease – 120‑129/70‑79 mmHg.
• In high‑risk patients, diastolic pressure should not be lowered below 70 mmHg, as excessive reduction may increase adverse cardiovascular events; the optimal diastolic range is 70‑79 mmHg. 58, 60

Initiation of Pharmacologic Therapy

• For confirmed hypertension (office ≥ 140/90 mmHg), lifestyle measures and pharmacologic treatment should be started simultaneously and not delayed beyond 3 months; early initiation reduces cardiovascular risk irrespective of baseline risk. 58, 59
• For elevated BP (130‑139/80‑89 mmHg), intensive lifestyle modification for 3 months is first‑line; pharmacologic therapy is added if BP remains ≥ 130/80 mmHg and any high‑risk condition is present (10‑year ASCVD risk ≥ 10 %, established CVD, diabetes, CKD stage ≥ 3 or albuminuria ≥ 300 mg/day, hypertension‑mediated organ damage, or familial hypercholesterolemia). 58, 60

First‑Line Pharmacologic Options

• The ESC endorses four first‑line drug classes—thiazide/thiazide‑like diuretics, ACE inhibitors, angiotensin‑receptor blockers (ARBs), and long‑acting dihydropyridine calcium‑channel blockers (CCBs)—each producing an average office BP reduction of ≈ 9/5 mmHg. 58, 59, 62
• Stage 1 hypertension (140‑159/90‑99 mmHg): initiate single‑agent monotherapy, titrate upward as needed, and reassess monthly until target is reached. 62
• Stage 2 hypertension (≥ 160/100 mmHg or > 20/10 mmHg above goal): begin with a two‑drug combination from different first‑line classes, preferably as a single‑pill formulation; this strategy markedly improves adherence. 62, 58, 59, 60
• Preferred two‑drug combos (ESC):

Population‑Specific First‑Line Choices

• Black patients without heart failure or CKD: start with a thiazide diuretic (chlorthalidone preferred) or a CCB; ACE inhibitors/ARBs are 30‑36 % less effective for stroke prevention due to lower renin activity. 62
• Diabetes mellitus: ACE inhibitor or ARB is preferred to protect renal function, especially with albuminuria ≥ 300 mg/day; target BP < 130/80 mmHg. 61
• Chronic kidney disease (stage ≥ 3 or albuminuria ≥ 300 mg/day): ACE inhibitor or ARB is first‑line to slow eGFR decline and reduce proteinuria; target BP < 130/80 mmHg. 61
• Pregnancy: use methyldopa, extended‑release nifedipine, or labetalol; ACE inhibitors, ARBs, and direct renin inhibitors are absolutely contraindicated. Target BP < 140/90 mmHg while avoiding diastolic < 80 mmHg. 59

Treatment Escalation

• If BP remains uncontrolled on a two‑drug regimen, ESC recommends escalation to triple therapy (ACE inhibitor or ARB + CCB + thiazide/thiazide‑like diuretic), preferably as a single‑pill combination. 58, 59
• Resistant hypertension (BP ≥ 130/80 mmHg on ≥ 3 drugs including a diuretic):

Lifestyle Recommendations (Applicable to All Adults with BP ≥ 120/70 mmHg)

• Sodium intake ≈ 2 g/day (≈ 5 g salt). 58
• Increase potassium intake 0.5‑1.0 g/day via potassium‑enriched salt or fruits/vegetables; monitor serum potassium in CKD or when using potassium‑sparing agents. 59
• Aerobic exercise ≥ 150 min/week moderate‑intensity (or ≥ 75 min/week vigorous) plus resistance training 2‑3 times/week. 58
• Weight management: aim for BMI 20‑25 kg/m² and waist < 94 cm (men) or < 80 cm (women). 58
• Adopt Mediterranean or DASH dietary patterns. 58
• Alcohol < 100 g/week of pure alcohol; preferably abstain. 58
• Limit free sugars to ≤ 10 % of total energy; avoid sugar‑sweetened beverages. 58, 59
• Smoking cessation is mandatory and independently reduces cardiovascular events. 58, 61

Monitoring and Follow‑Up

• After initiating or adjusting therapy, review patients monthly until BP target is achieved; once controlled, schedule follow‑up every 3‑5 months. 62
• Baseline labs: serum creatinine, eGFR, potassium, fasting glucose, lipid profile, urine albumin‑to‑creatinine ratio. 58
• When prescribing ACE inhibitors, ARBs, or diuretics, repeat creatinine, eGFR, and potassium within 1‑2 weeks of start, after each dose increase, and annually thereafter.

Agents to Avoid or Use With Caution

• β‑Blockers should not be first‑line in uncomplicated hypertension, especially in patients > 60 years, because they are ≈ 36 % less effective than CCBs and ≈ 30 % less effective than thiazides for stroke prevention; reserve for compelling indications (angina, post‑MI, HFrEF, atrial fibrillation). 62, 58, 59
• Dual RAS blockade (ACE inhibitor + ARB or addition of a direct renin inhibitor) is contraindicated due to increased risk of hyperkalemia and acute kidney injury without added cardiovascular benefit. 58, 59
• Renal denervation is not recommended as first‑line therapy because adequately powered outcome trials demonstrating safety and cardiovascular benefit are lacking. 58, 59